Clinical experience with inactivated, virosomal influenza vaccine. (Q64913368)

30 June 2019

title

Clinical experience with inactivated, virosomal influenza vaccine. (English)

1 reference

30 June 2019

1 reference

1 reference

de Bruijn IA

1

1 reference

30 June 2019

Nauta J

2

1 reference

30 June 2019

Cramer WC

3

1 reference

30 June 2019

Gerez L

4

1 reference

30 June 2019

Palache AM

5

1 reference

30 June 2019

language of work or name

English

0 references

publication date

1 July 2005

1 reference

30 June 2019

published in

Vaccine

1 reference

30 June 2019

volume

23 Suppl 1

1 reference

30 June 2019

page(s)

S39-49

1 reference

30 June 2019

Antibody induction by influenza vaccines in the elderly: a review of the literature

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Impact of respiratory virus infections on persons with chronic underlying conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Immunity to influenza in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Immunogenicity of new virosome influenza vaccine in elderly people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Virosome influenza vaccine in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

New estimates of influenza-related pneumonia and influenza hospitalizations among the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Influenza A virus specific T cell immunity in humans during aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Confronting the avian influenza threat: vaccine development for a potential pandemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Influenza virosomes as an efficient system for adjuvanted vaccine delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

Influenza virosomes in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.020

10.1016/J.VACCINE.2005.04.020

7 January 2021

Identifiers

DOI

1 reference

30 June 2019

PubMed ID

16005120

1 reference

30 June 2019